Moneycontrol PRO
Upcoming Event:Super25 3.0- India’s Largest Online Stock Traders Conference brought to you by Moneycontrol Pro & Espresso

Tatva Chinta Pharma falls over 9% at open on decline in margins

The stock hit a low of Rs 2597.05 intraday. At 9.20 am, the scrip was trading at Rs 2655 on BSE down 7.4% from its previous close.

January 18, 2022 / 09:32 AM IST
stocks_decline

stocks_decline


Shares of Tatva Chintan Pharma Chem Ltd on Tuesday declined over 9% in the opening after the firm reported a sequential fall in revenue and operating margins for the December quarter.
 The stock hit a low of Rs 2597.05 intraday. At 9.20 am, the scrip was trading at Rs 2655 on BSE down 7.4% from its previous close.

The firm reported Ebitda margins at 27.26% in the December quarter against 31.31% for the previous period. Ebitda was down 26.87% from a quarter ago to Rs 28.53 crore. Net profit margin fell to 21.79% from 25.64% a quarter ago.

Analysts say that the fall in operating margins was due to a rise in input costs. Costs of materials consumed rose 6% quarter on quarter while year on year they surged over 66%.

Net profit for the quarter stood at Rs 22.81 crore, down 29.62% sequentially while revenue declined 15.33% to Rs 104.67 crore.

Recently, brokerage firm ICICI Securities initiated coverage on the stock with buy rating and gave a target price at Rs 2920 a share. It claimed that the firm is a strong play on smart and green chemistry.

Close

The company listed in July 2021 after raising around Rs 225 crore via fresh issue and Rs 225 crore through offer for sale. Since listing, the firm has surged over 165% from its issue price of Rs 1083 apiece.

The company has said its expansion of Dahej manufacturing facility and upgrade of an R&D facility in Vadodara is underway.



Download your money calendar for 2022-23 here and keep your dates with your moneybox, investments, taxes

Moneycontrol Research
first published: Jan 18, 2022 09:32 am
Sections
ISO 27001 - BSI Assurance Mark